At today's meeting, the Food and Drug Administration's advisers refused to support Actavis Plc's experimental drug meant to reduce high blood pressure. The pill is made by combining two existing drugs meant to lower high BP.
The U.S. regulatory advisers said the drug does not show any additional benefit over the two drugs alone. Therefore, the drug should not be approved. The panel voted 6 to 4 against recommending the drug.